Medical Genetics Branch, NHGRI, NIH, Bethesda, MD, USA.
FDNA Inc., Boston, MA, USA.
Mol Genet Metab. 2021 Nov;134(3):274-280. doi: 10.1016/j.ymgme.2021.09.008. Epub 2021 Oct 5.
Gaucher disease (GD) is a rare lysosomal storage disorder that is divided into three subtypes based on presentation of neurological manifestations. Distinguishing between the types has important implications for treatment and counseling. Yet, patients with neuronopathic forms of GD, types 2 and 3, often present at young ages and can have overlapping phenotypes. It has been shown that new technologies employing artificial intelligence and facial recognition software can assist with dysmorphology assessments. Though classically not associated nor previously described with a dysmorphic facial phenotype, this study investigated whether a facial recognition platform could distinguish between photos of patients with GD2 and GD3 and discriminate between them and photos of healthy controls. Each cohort included over 100 photos. A cross validation scheme including a series of binary comparisons between groups was used. Outputs included a composite photo of each cohort and either a receiver operating characteristic curve or a confusion matrix. Binary comparisons showed that the software could correctly group photos at least 89% of the time. Multiclass comparison between GD2, GD3, and healthy controls demonstrated a mean accuracy of 76.6%, compared to a 37.7% chance for random comparison. Both GD2 and GD3 have now been added to the facial recognition platform as established syndromes that can be identified by the algorithm. These results suggest that facial recognition and artificial intelligence, though no substitute for other diagnostic methods, may aid in the recognition of neuronopathic GD. The algorithm, in concert with other clinical features, also appears to distinguish between young patients with GD2 and GD3, suggesting that this tool can help facilitate earlier implementation of appropriate management.
戈谢病(GD)是一种罕见的溶酶体贮积症,根据神经表现可分为三种亚型。区分类型对治疗和咨询具有重要意义。然而,神经病变型 GD 患者(2 型和 3 型)通常在年幼时出现,并且可能具有重叠的表型。已经表明,采用人工智能和面部识别软件的新技术可以辅助进行发育异常评估。尽管经典上与发育异常的面部表型无关,也未曾描述过与该表型相关,但本研究调查了面部识别平台是否可以区分 GD2 和 GD3 患者的照片,并将其与健康对照组的照片区分开来。每个队列都包括 100 多张照片。使用包括一系列组间二进制比较的交叉验证方案。输出包括每个队列的综合照片,以及接收者操作特征曲线或混淆矩阵。二进制比较表明,该软件至少可以 89%的时间正确地对照片进行分组。GD2、GD3 和健康对照组之间的多类比较表明,平均准确率为 76.6%,而随机比较的可能性为 37.7%。GD2 和 GD3 现在都已被添加到面部识别平台中,作为可以通过算法识别的既定综合征。这些结果表明,面部识别和人工智能虽然不能替代其他诊断方法,但可能有助于识别神经病变型 GD。该算法还与其他临床特征一起,似乎可以区分 GD2 和 GD3 的年轻患者,表明该工具可以帮助更早地实施适当的管理。